Olema Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
De CEO Olema Pharmaceuticals is Sean Bohen, benoemd in Sep2020, heeft een ambtstermijn van 4.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.15M, bestaande uit 20.5% salaris en 79.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.25% van de aandelen van het bedrijf, ter waarde $ 1.27M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 4.3 jaar.
Belangrijke informatie
Sean Bohen
Algemeen directeur
US$3.2m
Totale compensatie
| Percentage CEO-salaris | 20.5% |
| Dienstverband CEO | 4.2yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 3.5yrs |
| Gemiddelde ambtstermijn bestuur | 4.3yrs |
Recente managementupdates
Recent updates
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Aug 29
Olema Pharmaceuticals: Still Merits A Small Holding
Jun 17Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
May 11Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
Mar 28Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Mar 04Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
Nov 09We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Jun 11Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?
Mar 01Olema Oncology grants stock options for 58.3K shares
Oct 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 13Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18
Aug 09Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype
Jul 21We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth
May 29Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 08Our Take On Olema Pharmaceuticals
Jan 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 19We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth
Jun 04Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 19
Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$123m |
| Jun 30 2024 | n/a | n/a | -US$110m |
| Mar 31 2024 | n/a | n/a | -US$99m |
| Dec 31 2023 | US$3m | US$647k | -US$97m |
| Sep 30 2023 | n/a | n/a | -US$96m |
| Jun 30 2023 | n/a | n/a | -US$97m |
| Mar 31 2023 | n/a | n/a | -US$110m |
| Dec 31 2022 | US$6m | US$616k | -US$105m |
| Sep 30 2022 | n/a | n/a | -US$100m |
| Jun 30 2022 | n/a | n/a | -US$95m |
| Mar 31 2022 | n/a | n/a | -US$79m |
| Dec 31 2021 | US$3m | US$595k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$60m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$11m | US$178k | -US$24m |
Compensatie versus markt: De totale vergoeding ($USD 3.15M ) Sean } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.14M ).
Compensatie versus inkomsten: De vergoeding van Sean is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Sean Bohen (57 yo)
4.2yrs
Tenure
US$3,152,370
Compensatie
Dr. Sean P. Bohen, M.D., Ph.D. has been a Director at AltruBio, Inc. He is the Chief Executive Officer and Director of Olema Pharmaceuticals, Inc. since September 2020 and serves as its President. He serve...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 4.2yrs | US$3.15m | 0.25% $ 1.3m | |
| Chief Operating & Financial Officer | 4.4yrs | US$1.55m | 0.89% $ 4.5m | |
| Chief Medical Officer | 2.8yrs | US$1.30m | 0.16% $ 788.7k | |
| Vice President of Corporate Communications | less than a year | geen gegevens | geen gegevens | |
| Senior VP & Head of People | no data | geen gegevens | geen gegevens | |
| Chief Discovery & Non-Clinical Development Officer | 4.4yrs | US$200.00k | 1.3% $ 6.5m | |
| VP of Finance & Controller | 1.8yrs | geen gegevens | geen gegevens |
3.5yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van OLMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 4.2yrs | US$3.15m | 0.25% $ 1.3m | |
| Independent Director | 11.8yrs | US$176.65k | 0.67% $ 3.4m | |
| Independent Director | 4.3yrs | US$180.15k | 0.15% $ 736.4k | |
| Independent Chairperson of the Board | 4.3yrs | US$198.65k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 3.6yrs | US$11.81k | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 4yrs | US$158.15k | 0% $ 0 | |
| Independent Director | 1.1yrs | US$280.21k | 0% $ 0 | |
| Independent Director | 4.7yrs | US$171.15k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$163.15k | 0% $ 0 | |
| Independent Director | 6.3yrs | US$165.15k | 0% $ 0 | |
| Director | 18.3yrs | US$1.33m | 1.53% $ 7.7m |
4.3yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van OLMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).